Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $1.7 per share a year ago. These ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Sage Therapeutics, Inc. (SAGE) reports results for the quarter ended December 2024. While this widely-known consensus ...

Sage Therapeutics (NASDAQ:SAGE) reports that it expects to announce topline data from a Phase 2 clinical trial evaluating SAGE-217 in women with postpartum depression (PPD) in Q4. SAGE-217, a ...

Despite Black women being the fastest-growing community of successful entrepreneurs in the US, with a growth rate of over 18% since 2017, only five percent of the surveyed founders have been able to ...

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.70 per share versus the Zacks Consensus Estimate of a loss of $1.68. This compares to loss of $2.68 per share a year ago. These ...